As lymphoma treatments become less cookie-cutter and more custom, the Leukemia & Lymphoma Society Chief Medical Officer Gwen Nichols, MD, shares how healthcare executives need to alter their approach to managing therapy regimens to increase cure rates and survivorship.
As lymphoma treatments become less cookie-cutter and more custom, the Leukemia & Lymphoma Society Chief Medical Officer Gwen Nichols, MD, shares how healthcare executives need to alter their approach to managing therapy regimens to increase cure rates and survivorship.
